In “Immovable Object, Meet Unstoppable Force,” Pillar VC’s Thomas de Vlaam reflects on the scientific complexity of endometriosis, the scale of its unmet need, and the convergence of people and technology behind Metri Bio. The article traces Ashley Abel’s path from Yale research to building a company focused on human-relevant models and the discovery of the first disease-modifying drug targets for endometriosis.
